shares remained in focus on Friday after the company said the US Food and Drug Administration (FDA) issued Import Alert 66-40 for its Silvassa manufacturing facility.
The stock traded largely unchanged at ₹424.35 on the NSE at around 10.12 am.
The FMCG major clarified that the regulatory action pertains only to a small section of the Silvassa plant and is not expected to have any material impact on its financial performance or operations.
According to the company, the domestic market remain unaffected by the import alert.
Dabur further said it is actively engaging with the US FDA and is working on preventive action plans to address the observations and resolve the matter.
The company maintained that the development does not impact its broader manufacturing operations and does not pose any significant risk to its business performance.